The Business of AI in Healthcare: Keynote by Philip Low, CEO,NeuroVigil followed by high profile Panel

October 25, 2017 @ 5:30 pm – 8:30 pm
Qualcomm Auditorium
5775 Morehouse Dr
San Diego, CA 92121
Anita Rusch
858-771-MIT1 (858-771-6481)

PROGRAM:  The business of AI —  solving the grand challenges in Health Care

DESCRIPTION:   How can Artificial Intelligence (AI) be applied to bend the $ 3.2 trillion a year healthcare cost curve, yet allow life science companies to create capital efficient business models that attract investors?  Learn from the most prominent tech and life science leaders about challenges and opportunities with AI and Healthcare. 

There is little doubt that transformational change is coming (AI/Machine Learning), and tech companies ranging in size from small startups to corporate titans like IBM and GE are scrambling to gain a foothold in this emerging field. The sector represents a lucrative-but-daunting target for investors—complicated by regulatory issues, a healthcare system that separates the interests of patients, providers, and payers, and an investment timeline that can take 10 years or more to realize.

Illumina found customers for its gene sequencing technology and data services at genomic research centers, clinical research organizations, research institutions, and biotech and pharmaceutical companies. But, is that a model that can be replicated? In other words, if there was a business built around analyzing data from the microbiome, say, what would it look like?

CureMatch is taking a direct-to-consumer approach, in which cancer patients pay CureMatch to recommend the top three combinations of chemotherapy drugs for each patient’s cancer. The recommendations, based on information in a patient’s own medical record, is intended to help cancer specialists choose a treatment regimen. CureMatch says it uses supercomputer processing to sort through millions of possible three-drug combinations, assessing each combination for factors like unwanted drug-drug interactions, and correlating genomic data to rank the best drug combinations for a specific patient.

KEYNOTE:  Philip Low, PhD, Founder, Chairman & C.E.O., NeuroVigil, Inc.

MODERATOR:  Rick Valencia, President, Qualcomm Life


  1. Kim Kamdar, Ph.D., Partner, Domain Associates
  2. Navid Alipour, Managing Partner, Analytics Ventures
  3. Joshua Windmiller, Co-Founder and CTO, BioLinq



5:30: Registration, Appetizers and Networking
6:30: Presentation
7:45: Audience Q & A
8:00: Program Concludes, Networking, Coffee & Dessert until 8:30

MITEF Members and MITEF Sponsors: Free
Non-members: $65
MIT Alums:  $50
​​On-Site: $75

NOTE:  Online Registration ends at noon the day of the event.  After that time, you may register on-site for $75

PAYPAL is our payment processor and accepts ALL MAJOR Credit Cards.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *